Look differently

Invenia ABUS
Automated Breast Ultrasound
Invenia™ ABUS

from GE Healthcare offers a view beyond mammography, with breast screening technology that looks differently.
The unseen risk.

Having dense breasts increases a woman’s likelihood to develop cancer four to six times\(^1\). Which makes it challenging to detect breast cancer with mammography alone.

This is a significant problem. Over 40% of women in Australia\(^1\) and New Zealand\(^2\) have dense breast tissue, which can mask the appearance of tumours and limit the performance of mammography. As breast density increases, the accuracy of mammograms decrease.

For women with dense breasts, there is now a screening technology that can effectively detect cancer to deliver confidence and peace of mind.
Enhanced detection.

55% relative increase in invasive cancers over mammography alone in dense breasted women when Invenia ABUS is used in conjunction with mammography (in patients with no prior breast interventions).⁴

GE Healthcare is the sole provider of FDA-approved technology designed for screening women with dense breast tissue.

Multiple clinical research studies⁵ demonstrate that when used as an adjunct to mammography, Invenia ABUS can detect invasive, node-negative cancers.

⁵Source: FDA PMA P110006 summary of safety and effectiveness.
Gently curved to follow the natural contour of the breast.

The Reverse-Curve™ transducer enhances both patient comfort and breast coverage with greater clarity during the exam.

The 15 cm ultra-broadband, wide field-of-view transducer automatically creates uniform compression across the entire breast for consistent, reproducible image quality independent of the operator.

Compression Assist
Automatically applies compression to the breast for patient comfort, operator ease and image acquisition quality.
A simple, automated procedure
Multi-planar and multi-volume correlation between the left anterior-posterior and left medial views allows for efficient and concise confirmation of this ill-defined mass.

The evidence is in the images.
Backed up by clinical research\textsuperscript{6}

Multiple clinical research studies demonstrate that radiologists can detect more cancers at an earlier, more treatable stage when using ABUS as an adjunctive screening tool with mammography.

Ninety-three percent of ABUS-detected cancers with normal or negative mammography were pathologically confirmed as invasive, in this asymptomatic screening population of women with dense breast tissue and no prior breast interventions. The majority of these invasive malignant lesions were also small and node negative.

A fast, efficient flow.

Designed for fast, efficient breast ultrasound workflow, Invenia ABUS Workstation displays 3D volumes in a patented, 2-mm-thick coronal slice from the skin to the chest wall. You can review, quickly interpret and archive patient exams.
Growing Awareness

For the 4 out of 10 women with dense breasts, screening with Invenia ABUS provides an additional option for breast care.

Invenia ABUS supporting early detection for better patient outcomes.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter – great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.

Better health for more people
Healthymagination is a GE shared commitment to create better health for more people. GE is investing in and innovating technologies that address doctors’ and patients’ needs. Invenia ABUS was created to improve the quality of breast care.

Disclosure Statement
The Invenia ABUS is indicated as an adjunct to mammography or breast cancer screening in asymptomatic women for whom screening mammography findings are normal or benign (BI-RADS® Assessment Category 1 or 2), with dense breast parenchyma (BI-RADS Composition/Density 3 or 4), and have not had previous clinical breast intervention. The device is intended to increase breast cancer detection in the described patient population. The Invenia ABUS may also be used for diagnostic ultrasound imaging of the breast in symptomatic women.

To learn more about Invenia ABUS, visit www.gehealthcare.com.au/inveniaabus, or scan the QR code to watch a video.